Current Issue


Clot concerns with adenovirus COVID-19 vaccines, antibody treatment recommendations and data

Based on reports of cerebral venous sinus thrombosis with the Johnson & Johnson (Janssen) COVID-19 vaccine, federal officials recommended a pause in its use, which will be reconsidered on April 23. The NIH updated its recommendations on monoclonal antibody treatments for outpatients.

Racial, economic disparities found in use of SGLT-2 inhibitors

Although use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors rose overall between 2015 and 2019, patients who were Black, Asian, female, or with lower household income had lower rates of prescriptions for the drug class than others with type 2 diabetes.

MKSAP Quiz: Numbness, tingling, weakness in arm

A 35-year-old woman is evaluated for numbness, tingling, and weakness in her left arm that radiates from the shoulder to the fingers. Her symptoms began 3 months ago and appear to be worsening. Following physical and neurological exams and electrodiagnostic studies, what is the most appropriate therapy for this patient?

ACP, AHA to launch Annals of Internal Medicine: Clinical Cases

The digital, open-access, peer-reviewed journal will publish case reports relevant to clinicians across the spectrum of medicine.

ACP announces representatives to project on equity and leadership for women

The Women's Wellness through Equity and Leadership (WEL) project is a collaborative effort among 10 leading U.S. medical associations to foster the development of the next wave of women physician leaders.

Reminder: ACP's Annual Business Meeting and Town Hall webinar set for May 2

Incoming Officers, new Regents, and first-year Governors will be introduced, and ACP's Treasurer, the current ACP President, and the ACP President-elect will report on the College's current status and priorities.

Put words in our mouth

ACP Internist Weekly wants readers to create captions for our new cartoon and help choose the winner. Pen the winning caption and win a $50 gift certificate good toward any ACP product, program, or service.